epilepsy
Conditions
Interventions
carbamazepine:carbamazepine
sodium valproate:sodium valproate
lamotrigine:lamotrigine
oxcarbazepine:oxcarbazepine
levetiracetam:levetiracetam
phenytoin:phenytoin
phenobarbital:phenobarbital
clonazepam:clonazepam
The antiepileptic drug 1:The antiepileptic drug 1 which will obtain marketing authorization in China in the future
The antiepileptic drug 2:The antiepileptic drug 2 which will obtain marketing authorization in China in the future
The antiepileptic drug 3:The antiepileptic drug 3 which will obtain marketing authorization in China in the future
Sponsors
The Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
13 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. The patients definitively diagnosed with epilepsy who were diagnosed and treated in our hospital; 2. Age 13 years and more, whom were prescribed with antiepileptic drugs.
Exclusion criteria
Exclusion criteria: 1. The patients who cannot be completed effectiveness/safety assessment at least for one time; 2. The patients who cannot cooperate with recording the seizures or have difficulty to record seizures; 3. The patients disagree to join this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retention rate;Seizure frequency;Seizure control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to seizure remission;Time to first seizure;Responder rate;Patterns of treatment response;psychosocial comorbidity rate;cognitive function in patients with epilepsy; | — |
Countries
China
Contacts
Public ContactZheng Rongyuan,Xu Huiqin
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed